Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

En global studie for å vurdere effekten av Durvalumab med Oleclumab eller Durvalumab med Monalizumab etter samtidig kjemoradiasjon hos pasienter med stadium III ikke-opererbar ikke-småcellet lungekreft (PACIFIC-9)

3. november 2026 oppdatert av: AstraZeneca

En fase III, dobbeltblind, placebokontrollert, randomisert, multisenter, internasjonal studie av Durvalumab Plus Oleclumab og Durvalumab Plus Monalizumab hos pasienter med lokalt avansert (stadium III), ikke-opererbar ikke-småcellet lungekreft (NSCLC) som ikke har progrediert Etter definitiv, platinabasert samtidig kjemoradiasjonsterapi

This is a Phase III, randomised, double-blind, multicentre, international study assessing the efficacy and safety of durvalumab (MEDI4736) in combination with oleclumab (MEDI9447) or durvalumab (MEDI4736) with monalizumab (IPH2201) in adults with locally advanced (Stage III), unresectable NSCLC, who have not progressed following platinum-based cCRT.

Studieoversikt

Studietype

Intervensjonell

Registrering (Faktiske)

1051

Fase

  • Fase 3

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

      • Box Hill, Australia, 3128
        • Research Site
      • East Melbourne, Australia, 3002
        • Research Site
      • Elizabeth Vale, Australia, 5112
        • Research Site
      • Gosford, Australia, 2250
        • Research Site
      • Heidelberg, Australia, 3084
        • Research Site
      • Kogarah, Australia, 2217
        • Research Site
      • South Brisbane, Australia, 4101
        • Research Site
      • St Albans, Australia, 3021
        • Research Site
      • Westmead, Australia, 2145
        • Research Site
      • Barretos, Brasil, 14784-400
        • Research Site
      • Belo Horizonte, Brasil, 30380-090
        • Research Site
      • Florianópolis, Brasil, 88034-000
        • Research Site
      • Fortaleza, Brasil, 60336-232
        • Research Site
      • Jaú, Brasil, 17210-120
        • Research Site
      • Natal, Brasil, 59075-740
        • Research Site
      • Porto Alegre, Brasil, 91350-200
        • Research Site
      • Porto Alegre, Brasil, 90610-001
        • Research Site
      • Recife, Brasil, 52010-075
        • Research Site
      • São Paulo, Brasil, 01323-903
        • Research Site
      • Uberlândia, Brasil, 38408-150
        • Research Site
      • Vitória, Brasil, 29043-260
        • Research Site
    • Alberta
      • Edmonton, Alberta, Canada, T6G 1Z2
        • Research Site
    • Ontario
      • Barrie, Ontario, Canada, L4M 6M2
        • Research Site
      • Hamilton, Ontario, Canada, L8V 5C2
        • Research Site
      • Kingston, Ontario, Canada, K7L 2V7
        • Research Site
      • London, Ontario, Canada, N6A 5W9
        • Research Site
      • Mississauga, Ontario, Canada, L5M 2N1
        • Research Site
      • Toronto, Ontario, Canada, M5G 2M9
        • Research Site
    • Quebec
      • Rimouski, Quebec, Canada, G5L 5T1
        • Research Site
      • Barranquilla, Colombia, 080020
        • Research Site
      • Bogota D.C., Colombia, 110131
        • Research Site
      • Medellín, Colombia, 050034
        • Research Site
      • Valledupar, Colombia, 200001
        • Research Site
    • California
      • San Diego, California, Forente stater, 92123
        • Research Site
    • Connecticut
      • New Haven, Connecticut, Forente stater, 06510
        • Research Site
    • Florida
      • Stuart, Florida, Forente stater, 34994
        • Research Site
    • Illinois
      • Urbana, Illinois, Forente stater, 61801
        • Research Site
    • Indiana
      • New Albany, Indiana, Forente stater, 47150
        • Research Site
    • Kentucky
      • Lexington, Kentucky, Forente stater, 40503
        • Research Site
      • Louisville, Kentucky, Forente stater, 40241
        • Research Site
    • Maryland
      • Annapolis, Maryland, Forente stater, 21401
        • Research Site
      • Baltimore, Maryland, Forente stater, 21201
        • Research Site
      • Baltimore, Maryland, Forente stater, 21229
        • Research Site
      • Bethesda, Maryland, Forente stater, 20817
        • Research Site
    • Michigan
      • Grand Rapids, Michigan, Forente stater, 49503
        • Research Site
    • Minnesota
      • Duluth, Minnesota, Forente stater, 55805
        • Research Site
    • Montana
      • Billings, Montana, Forente stater, 59101
        • Research Site
    • New Jersey
      • Ridgewood, New Jersey, Forente stater, 07450
        • Research Site
    • New York
      • Ithaca, New York, Forente stater, 14850
        • Research Site
    • North Carolina
      • Greensboro, North Carolina, Forente stater, 27403
        • Research Site
    • Ohio
      • Cleveland, Ohio, Forente stater, 44195
        • Research Site
      • Cleveland, Ohio, Forente stater, 44124
        • Research Site
      • Maumee, Ohio, Forente stater, 43537
        • Research Site
    • Oregon
      • Portland, Oregon, Forente stater, 97239
        • Research Site
    • Pennsylvania
      • Philadelphia, Pennsylvania, Forente stater, 19104
        • Research Site
      • York, Pennsylvania, Forente stater, 17403
        • Research Site
    • South Dakota
      • Sioux Falls, South Dakota, Forente stater, 57105
        • Research Site
    • Texas
      • Houston, Texas, Forente stater, 77030
        • Research Site
    • Virginia
      • Charlottesville, Virginia, Forente stater, 22908
        • Research Site
      • Fairfax, Virginia, Forente stater, 22031
        • Research Site
      • Fredericksburg, Virginia, Forente stater, 22408
        • Research Site
      • Richmond, Virginia, Forente stater, 23235
        • Research Site
    • Washington
      • Richland, Washington, Forente stater, 99352
        • Research Site
      • Spokane, Washington, Forente stater, 99204
        • Research Site
      • Tacoma, Washington, Forente stater, 98405
        • Research Site
    • Wisconsin
      • Milwaukee, Wisconsin, Forente stater, 53226
        • Research Site
      • Avignon, Frankrike, 84918
        • Research Site
      • Besançon, Frankrike, 25030
        • Research Site
      • Bordeaux, Frankrike, 33075
        • Research Site
      • Clermont-Ferrand, Frankrike, 63000
        • Research Site
      • Créteil, Frankrike, 94010
        • Research Site
      • Lorient, Frankrike, 56322
        • Research Site
      • Marseille, Frankrike, 13015
        • Research Site
      • Montpellier, Frankrike, 34298
        • Research Site
      • Rennes, Frankrike, 35033
        • Research Site
      • Rouen, Frankrike, 76031
        • Research Site
      • Toulouse, Frankrike, 31059
        • Research Site
      • Villejuif, Frankrike, 94805
        • Research Site
      • Brescia, Italia, 25123
        • Research Site
      • Florence, Italia, 50134
        • Research Site
      • Lucca, Italia, 55100
        • Research Site
      • Meldola, Italia, 47014
        • Research Site
      • Orbassano, Italia, 10043
        • Research Site
      • Parma, Italia, 43126
        • Research Site
      • Pavia, Italia, 27100
        • Research Site
      • Roma, Italia, 00128
        • Research Site
      • Himeji-shi, Japan, 670-8520
        • Research Site
      • Hiroshima, Japan, 730-0011
        • Research Site
      • Kashiwa, Japan, 227-8577
        • Research Site
      • Kurume-shi, Japan, 830-0011
        • Research Site
      • Natori-shi, Japan, 981-1293
        • Research Site
      • Niigata, Japan, 951-8566
        • Research Site
      • Osaka, Japan, 541-8567
        • Research Site
      • Sendai, Japan, 980-0873
        • Research Site
      • Tokushima, Japan, 770-8503
        • Research Site
      • Toon-shi, Japan, 791-0295
        • Research Site
      • Wakayama, Japan, 641-8510
        • Research Site
      • Anyang, Kina, 455000
        • Research Site
      • Beijing, Kina, 100021
        • Research Site
      • Changchun, Kina, 130021
        • Research Site
      • Changsha, Kina, 410013
        • Research Site
      • Changsha, Kina, 410008
        • Research Site
      • Guangzhou, Kina, 510060
        • Research Site
      • Guangzhou, Kina, 510062
        • Research Site
      • Guangzhou, Kina, 510700
        • Research Site
      • Hangzhou, Kina, 310022
        • Research Site
      • Hangzhou, Kina, 310002
        • Research Site
      • Hefei, Kina, 230031
        • Research Site
      • Hefei, Kina, 133500
        • Research Site
      • Kunming, Kina, 650118
        • Research Site
      • Linhai, Kina, 317000
        • Research Site
      • Nanchang, Kina, 330006
        • Research Site
      • Nanning, Kina, 530021
        • Research Site
      • Nantong, Kina, 226361
        • Research Site
      • Neijiang, Kina, 641000
        • Research Site
      • Ningbo, Kina, 315100
        • Research Site
      • Shaoguan, Kina, 512027
        • Research Site
      • Tianjin, Kina, 300060
        • Research Site
      • Wuhan, Kina, 430079
        • Research Site
      • Wuhan, Kina, 430022
        • Research Site
      • Wuhan, Kina, 430071
        • Research Site
      • Zhanjiang, Kina, 524001
        • Research Site
      • Zhengzhou, Kina, 450008
        • Research Site
      • Zhengzhou, Kina, 450000
        • Research Site
      • Zhongshan, Kina, 528403
        • Research Site
      • Lima, Peru, Lima 32
        • Research Site
      • Lima, Peru, 15038
        • Research Site
      • Lima, Peru, Lima 34
        • Research Site
      • Bydgoszcz, Polen, 85-796
        • Research Site
      • Gdansk, Polen, 80-952
        • Research Site
      • Koszalin, Polen, 75-581
        • Research Site
      • Poznan, Polen, 60-569
        • Research Site
      • Siedlce, Polen, 08-110
        • Research Site
      • Tomaszów Mazowiecki, Polen, 97-200
        • Research Site
      • Warsaw, Polen, 02-781
        • Research Site
      • Lisbon, Portugal, 1998-018
        • Research Site
      • Lisbon, Portugal, 1769-001
        • Research Site
      • Lisbon, Portugal, 1099-023
        • Research Site
      • Lisbon, Portugal, 1400-038
        • Research Site
      • Loures, Portugal, 2674-514
        • Research Site
      • Porto, Portugal, 4200-319
        • Research Site
      • Barcelona, Spania, 8035
        • Research Site
      • Barcelona, Spania, 8003
        • Research Site
      • Granada, Spania, 18016
        • Research Site
      • Madrid, Spania, 28034
        • Research Site
      • Madrid, Spania, 28040
        • Research Site
      • Santiago de Compostela, Spania, 15706
        • Research Site
      • Valencia, Spania, 46010
        • Research Site
      • Belfast, Storbritannia, BT9 7AB
        • Research Site
      • Bristol, Storbritannia, BS2 8ED
        • Research Site
      • Dundee, Storbritannia, DD1 9SY
        • Research Site
      • Edinburgh, Storbritannia, EH4 2XR
        • Research Site
      • London, Storbritannia, W6 8RF
        • Research Site
      • London, Storbritannia, NW1 2PG
        • Research Site
      • Middlesbrough, Storbritannia, TS4 3BW
        • Research Site
      • Poole, Storbritannia, BH15 2JB
        • Research Site
      • Torquay, Storbritannia, TQ2 7AA
        • Research Site
      • Truro, Storbritannia, TR1 3LJ
        • Research Site
      • Wolverhampton, Storbritannia, WV10 OQP
        • Research Site
      • Changwon-si, Sør -Korea, 51353
        • Research Site
      • Cheongju-si, Sør -Korea, 28644
        • Research Site
      • Seongnam-si, Sør -Korea, 13620
        • Research Site
      • Seoul, Sør -Korea, 03080
        • Research Site
      • Seoul, Sør -Korea, 03722
        • Research Site
      • Seoul, Sør -Korea, 05505
        • Research Site
      • Suwon, Sør -Korea, 16499
        • Research Site
      • Suwon, Sør -Korea, 16247
        • Research Site
      • Hsinchu, Taiwan, 300
        • Research Site
      • New Taipei City, Taiwan, 23561
        • Research Site
      • Taichung, Taiwan, 40705
        • Research Site
      • Taichung, Taiwan, 402
        • Research Site
      • Taipei, Taiwan
        • Research Site
      • Taipei, Taiwan, 11490
        • Research Site
      • Taoyuan City, Taiwan, 333
        • Research Site
      • Bangkok, Thailand, 10300
        • Research Site
      • Bangkok, Thailand, 10700
        • Research Site
      • Hat Yai, Thailand, 90110
        • Research Site
      • Khon Kaen, Thailand, 40002
        • Research Site
      • Khon Kaen, Thailand, 40000
        • Research Site
      • Lampang, Thailand, 52000
        • Research Site
      • Muang, Thailand, 50200
        • Research Site
      • Muang, Thailand, 22000
        • Research Site
      • Mueang, Thailand, 20000
        • Research Site
      • Naimuang, Thailand, 30000
        • Research Site
      • Ankara, Tyrkia (Türkiye), 06230
        • Research Site
      • Ankara, Tyrkia (Türkiye), 06800
        • Research Site
      • Ankara, Tyrkia (Türkiye), 06010
        • Research Site
      • Cordaleo, Tyrkia (Türkiye), 35575
        • Research Site
      • Diyarbakır, Tyrkia (Türkiye), 21280
        • Research Site
      • Goztepe Istanbul, Tyrkia (Türkiye)
        • Research Site
      • Erfurt, Tyskland, 99089
        • Research Site
      • Erlangen, Tyskland, 91054
        • Research Site
      • Essen, Tyskland, 45147
        • Research Site
      • Esslingen am Neckar, Tyskland, 73730
        • Research Site
      • Georgsmarienhütte, Tyskland, 49124
        • Research Site
      • Gütersloh, Tyskland, 33332
        • Research Site
      • Hanover, Tyskland, 30459
        • Research Site
      • Oldenburg, Tyskland, 26121
        • Research Site
      • Würzburg, Tyskland, 97080
        • Research Site
      • Haiphong, Vietnam, 180000
        • Research Site
      • Hanoi, Vietnam, 100000
        • Research Site
      • Ho Chi Minh City, Vietnam, 700000
        • Research Site

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

INCLUSION CRITERIA:

  • Participant must be ≥ 18 years at the time of screening.
  • Histologically- or cytologically-documented NSCLC and have been treated with concurrent CRT for locally advanced, unresectable (Stage III) disease
  • Provision of a tumour tissue sample obtained prior to CRT
  • Documented tumour PD-L1 status by central lab
  • Documented EGFR and ALK wild-type status (local or central).
  • Patients must not have progressed following definitive, platinum based, concurrent chemoradiotherapy
  • Participants must have received at least 2 cycles of platinum-based chemotherapy concurrent with radiation therapy
  • Participants must have received a total dose of radiation of 60 Gy ±10% (54 Gy to 66 Gy) as part of the chemoradiation therapy, to be randomised. Radiation therapy should be administered by intensity modulated RT (preferred) or 3D-conforming technique.
  • WHO performance status of 0 or 1 at randomization
  • Adequate organ and marrow function

EXCLUSION CRITERIA:

  • History of another primary malignancy except for malignancy treated with curative intent with no known active disease ≥5 years before the first dose of study intervention and of low potential risk for recurrence, adequately resected non-melanoma skin cancer and curatively treated in situ disease, or adequately treated carcinoma in situ or Ta tumours without evidence of disease.
  • Mixed small cell and non-small cell lung cancer histology.
  • Participants who receive sequential (not inclusive of induction) chemoradiation therapy for locally advanced (Stage III) unresectable NSCLC.
  • Participants with locally advanced (Stage III) unresectable NSCLC who have progressed during platinum-based cCRT.
  • Any unresolved toxicity CTCAE >Grade 2 from the prior chemoradiation therapy (excluding alopecia).
  • Participants with ≥grade 2 pneumonitis from prior chemoradiation therapy.
  • History of idiopathic pulmonary fibrosis, drug-induced pneumonitis, or idiopathic pneumonitis - regardless of time of onset prior to randomisation. Evidence of active non-CRT induced pneumonitis (≥ Grade 2), active pneumonia, active ILD, active or recently treated pleural effusion, or current pulmonary fibrosis - diagnosed in the past 6 months prior to randomization.
  • Active or prior documented autoimmune or inflammatory disorders (with exceptions)
  • Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Firemannsrom

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Arm A: Durvalumab and Oleclumab

Durvalumab on Day 1 of each 28-day cycle + Oleclumab on Days 1 and 15 of cycles 1 and 2, then on Day 1 of each subsequent 28-day cycle for up to 12 months

Durvalumab IV (intravenous infusion)

Oleclumab IV (intravenous infusion)

Eksperimentell: Arm B: Durvalumab and Monalizumab

Durvalumab + Monalizumab on Day 1 of each 28-day cycle for up to 12 months. Placebo infusion will be administered on Day 15 of cycles 1 and 2 only

Durvalumab IV (intravenous infusion)

Monalizumab IV (intravenous infusion)

Placebo IV (intravenous infusion)

Aktiv komparator: Arm C: Durvalumab and Placebo

Durvalumab on Day 1 of each 28-day cycle + Placebo on Days 1 and 15 of cycles 1 and 2, then on Day 1 of each subsequent 28-day cycle for up to 12 months

Durvalumab IV (intravenous infusion)

Placebo IV (intravenous infusion)

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Progression Free Surival (PFS)
Tidsramme: Up to 5 years after first patient randomized.

Progression Free Survival (PFS) as assessed by BICR, per RECIST 1.1.

Up to 5 years after first patient randomized.

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Overall Survival (OS)
Tidsramme: Up to 9 years after first patient randomized

Overall survival (OS)

Up to 9 years after first patient randomized
Objective response rate (ORR)
Tidsramme: Up to 5 years after first patient randomized

Objective response rate (ORR) per RECIST 1.1 as assessed by BICR

Up to 5 years after first patient randomized
Overall survival (OS) at 24 months
Tidsramme: Up to 9 years after first patient randomized

Overall survival (OS) at 24 months

Up to 9 years after first patient randomized
Duration of response (DoR)
Tidsramme: Up to 5 years after first patient randomized

Duration of response (DoR) per RECIST 1.1 as assessed by BICR

Up to 5 years after first patient randomized
Progression free survival (PFS) at 6, 12, 18, and 24 months
Tidsramme: From date of randomization until 24 months

Progression free survival (PFS) at 6, 12, 18, and 24 months respectively, per RECIST 1.1 as assessed by BICR

From date of randomization until 24 months
Time from randomization to second progression (PFS2)
Tidsramme: Up to 5 years after first patient randomized

Time from randomization to second progression (PFS2)

Up to 5 years after first patient randomized
Time from randomization to first date of distant metastasis or death (TTDM)
Tidsramme: Up to 5 years after first patient randomized

Time from randomization to first date of distant metastasis or death (TTDM)

Up to 5 years after first patient randomized
Time from randomization to start date of first subsequent therapy (TFST)
Tidsramme: Up to 9 years after first patient randomized

Time from randomization to start date of first subsequent therapy (TFST)

Up to 9 years after first patient randomized
Progression free survival (PFS) as assessed by Investigator
Tidsramme: Up to 5 years after first patient randomized

Progression free survival (PFS) as assessed by Investigator

Up to 5 years after first patient randomized
IHC analysis of PD-L1 TC expression
Tidsramme: Up to 5 years after first patient randomized

IHC analysis of PD-L1 TC expression relative to efficacy outcomes

Up to 5 years after first patient randomized
Concentration of Durvalumab
Tidsramme: From date of randomization until 3 months after date of last IP dose

To assess the Pharmacokinetics of Durvalumab when in combination with Monalizumab or Oleclumab - serum peak and trough concentrations

From date of randomization until 3 months after date of last IP dose
Anti-drug antibodies (ADAs)
Tidsramme: From date of randomization until 3 months after date of last IP dose

The immunogenicity of durvalumab, oleclumab, and monalizumab as assessed by presence of anti-drug antibodies (ADAs)

From date of randomization until 3 months after date of last IP dose
Time to deterioration in pulmonary symptoms (TTFCD)
Tidsramme: Up to 5 years after last patient randomized

Time to deterioration in pulmonary symptoms (TTFCD)

Up to 5 years after last patient randomized
Concentration of Oleclumab
Tidsramme: From date of randomization until 3 months after last dose of IP

To assess the Pharmacokinetics of Oleclumab when in combination with Durvulumab - serum peak and trough concentrations

From date of randomization until 3 months after last dose of IP
Concentration of Monalizumab
Tidsramme: From date of randomization until 3 months after last dose of IP

To assess the Pharmacokinetics of Monalizumab when in combination with Durvalumab - serum peak and trough concentrations

From date of randomization until 3 months after last dose of IP

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Etterforskere

  • Hovedetterforsker: Fabrice Barlesi, MD, Gustave Roussy, Cancer Campus, Grand Paris

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

7. februar 2022

Primær fullføring (Antatt)

8. januar 2027

Studiet fullført (Antatt)

2. juli 2030

Datoer for studieregistrering

Først innsendt

14. januar 2022

Først innsendt som oppfylte QC-kriteriene

2. februar 2022

Først lagt ut (Faktiske)

3. februar 2022

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

4. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

3. november 2026

Sist bekreftet

1. oktober 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • D9078C00001
  • 2021-004346-37 (EudraCT-nummer)
  • 2023-503999-24-00 (Registeridentifikator: Clinical Trial Information System (CTIS))
  • 2023 (U.S. NIH-stipend/kontrakt)

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

IPD-delingstidsramme

AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Tilgangskriterier for IPD-deling

When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

IPD-deling Støtteinformasjonstype

  • STUDY_PROTOCOL
  • SEVJE

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere